| ISIN | LU2488093530 |
|---|---|
| Valor Number | 119401713 |
| Bloomberg Global ID | |
| Fund Name | Kieger Impact Healthcare Fund Class B CHF Accumulating |
| Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
| Fund Provider | Kieger AG |
| Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
| Distributor(s) | |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
| Peculiarities |
| Current Price * | 79.05 CHF | 30.10.2025 |
|---|---|---|
| Previous Price * | 79.20 CHF | 29.10.2025 |
| 52 Week High * | 98.71 CHF | 30.01.2025 |
| 52 Week Low * | 73.38 CHF | 07.08.2025 |
| NAV * | 79.05 CHF | 30.10.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 49,697,645 | |
| Unit/Share Assets *** | 7,541 | |
| Trading Information SIX | ||
| YTD Performance | -10.59% |
31.12.2024 - 30.10.2025
31.12.2024 30.10.2025 |
|---|---|---|
| 1 month | +4.83% |
30.09.2025 - 30.10.2025
30.09.2025 30.10.2025 |
| 3 months | +2.04% |
30.07.2025 - 30.10.2025
30.07.2025 30.10.2025 |
| 6 months | -1.61% |
30.04.2025 - 30.10.2025
30.04.2025 30.10.2025 |
| 1 year | -9.70% |
30.10.2024 - 30.10.2025
30.10.2024 30.10.2025 |
| 2 years | -1.48% |
30.10.2023 - 30.10.2025
30.10.2023 30.10.2025 |
| 3 years | -20.95% |
20.03.2023 - 30.10.2025
20.03.2023 30.10.2025 |
| 5 years | - | - |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sandoz Group AG Registered Shares | 4.00% | |
|---|---|---|
| Axsome Therapeutics Inc | 3.99% | |
| ResMed Inc | 3.92% | |
| Humana Inc | 3.92% | |
| Hologic Inc | 3.87% | |
| RadNet Inc | 3.80% | |
| BioNTech SE ADR | 3.79% | |
| Hikma Pharmaceuticals PLC | 3.55% | |
| DexCom Inc | 3.54% | |
| Sanofi SA | 3.51% | |
| Last data update | 31.07.2025 | |
| TER *** | 1.22% |
|---|---|
| TER date *** | 30.09.2023 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.00% |
| Ongoing Charges *** | 1.22% |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |